These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 36943311

  • 1. Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor positron emission tomography/computed tomography imaging in real-life setting.
    Kostiainen I, Majala S, Schildt J, Parviainen H, Kauhanen S, Seppänen H, Miettinen PJ, Matikainen N, Ryhänen EM, Schalin-Jäntti C.
    Eur J Endocrinol; 2023 May 10; 188(5):421-429. PubMed ID: 36943311
    [Abstract] [Full Text] [Related]

  • 2. Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.
    Mennetrey C, Le Bras M, Bando-Delaunay A, Al-Mansour L, Haissaguerre M, Batisse-Lignier M, Ouvrard E, Ansquer C, Walter T, de Mestier L, Kelly A, Tlili G, Giraud S, North MO, Odou MF, Goichot B, Cuny T, Loundou A, Romanet P, Imperiale A, Taïeb D.
    J Clin Endocrinol Metab; 2022 Apr 19; 107(5):e2056-e2064. PubMed ID: 34940846
    [Abstract] [Full Text] [Related]

  • 3. Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.
    Xu J, Xu X, Zhang M, Liu W, Chen J, Song S.
    Neuroendocrinology; 2024 Apr 19; 114(9):866-871. PubMed ID: 38471465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.
    Said M, Krogh J, Feldt-Rasmussen U, Rasmussen ÅK, Kristensen TS, Rossing CM, Johannesen HH, Oturai P, Holmager P, Kjaer A, Klose M, Langer S, Knigge U, Andreassen M.
    J Neuroendocrinol; 2023 Aug 19; 35(8):e13322. PubMed ID: 37564005
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.
    Eur J Nucl Med Mol Imaging; 2016 Jul 19; 43(7):1258-66. PubMed ID: 26819103
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.
    Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS.
    Front Endocrinol (Lausanne); 2021 Jul 19; 12():654975. PubMed ID: 34163434
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR.
    J Clin Endocrinol Metab; 2017 Jun 01; 102(6):1926-1933. PubMed ID: 28323985
    [Abstract] [Full Text] [Related]

  • 13. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB, Lodewijk L, Moelans CB, Offerhaus GJA, Pieterman CRC, Morsink FH, Dekkers OM, de Herder WW, Hermus AR, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Brosens LAA, Dreijerink KMA, Borel Rinkes IHM, Timmers HTM, Valk GD, Vriens MR.
    Eur J Endocrinol; 2018 Sep 01; 179(3):153-160. PubMed ID: 29903750
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
    Cingarlini S, Ortolani S, Salgarello M, Butturini G, Malpaga A, Malfatti V, DʼOnofrio M, Davì MV, Vallerio P, Ruzzenente A, Capelli P, Citton E, Grego E, Trentin C, De Robertis R, Scarpa A, Bassi C, Tortora G.
    Pancreas; 2017 Jan 01; 46(1):42-47. PubMed ID: 27906872
    [Abstract] [Full Text] [Related]

  • 16. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
    Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK.
    World J Surg; 2017 Jun 01; 41(6):1521-1527. PubMed ID: 28138732
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma.
    Serfling SE, Zhi Y, Megerle F, Fassnacht M, Buck AK, Lapa C, Werner RA.
    Endocrine; 2022 Oct 01; 78(1):169-176. PubMed ID: 35751778
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
    Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP.
    J Nucl Med; 2020 Nov 01; 61(11):1560-1569. PubMed ID: 32169914
    [Abstract] [Full Text] [Related]

  • 20. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
    Rufini V, Lorusso M, Inzani F, Pasciuto T, Triumbari EKA, Grillo LR, Locco F, Margaritora S, Pescarmona E, Rindi G.
    Eur J Nucl Med Mol Imaging; 2022 Oct 01; 49(12):4182-4193. PubMed ID: 35674739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.